Tsewang Tashi, MD, discusses the efficacy and tolerability of targeted therapies like avapritinib for patients with indolent systemic mastocytosis.
Best Practices in Managing Indolent Systemic Mastocytosis (ISM)
Tracy I. George, MD, discusses testing considerations in indolent systemic mastocytosis, including the role of serum tryptase and KIT D816V testing.
Andrew Kuykendall, MD, discusses the importance of a nuanced, multidisciplinary approach to expedite the diagnosis of indolent systemic mastocytosis.
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts NDA for Zanzalintinib Plus Atezolizumab in Pretreated mCRC
2
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
3
Retrospective, Real-World Analysis Shows Improved OS With Apalutamide Over Darolutamide in mCSPC
4
Five Under 5: Top Oncology Videos for the Week of 1/25
5